Tagged with vaccines

Vaccines Jeremy Farrar, director of the Wellcome Trust, spoke to Financial Times correspondent Vanessa Kortekaas on 25 June 2020 about the global race to develop a COVID-19 vaccine. He emphasized the importance of prioritising access to at-risk populations, supply chain scale issues that must be considered, why there is no future…

France French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679 million in vaccine manufacturing operations in the next two years. This announcement came shortly after news of further rounds of layoffs of research staff working on cardiovascular diseases and…

Belgium In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally can contribute to the rapid development of a safe and effective COVID-19 vaccine. Dr Hanon outlines the challenges inherent in…

Coronavirus Against the backdrop of an unprecedented collaborative global push to develop a COVID-19 vaccine, pharma industry executives and patient advocacy representatives at the BIO 2020 digital conference discussed the progress made towards developing a HIV vaccine and what developers of potential COVID-19 treatments and vaccines can learn from it.  …

China Chinese biotech CanSinoBIO is racing against the clock to have a COVID-19 vaccine ready to begin production in early 2021. The firm’s senior VP of International Business Pierre Morgon reflects on CanSinoBIO’s progress thus far and a timeline of what we can realistically expect if and when Chinese authorities give…

Vaccines Vaccines are back on top of the pharma priority list as companies race against the clock to develop the first effective COVID-19 vaccine. Below we present the top 10 pharma companies producing vaccines globally, based on revenues from 2017 and projected revenues from 2024. GSK leads the pack with over…

China Pierre A Morgon, SVP International Business for CanSino Biotechnology (CanSinoBIO) – a Chinese vaccine biotech developing one of the frontrunner COVID-19 vaccine candidates – shares how his extensive international career brought him to CanSinoBIO, the deeply-rooted public health orientation of the vaccines sector, the complex realities of developing and deploying…

Coronavirus Highly potent neutralizing antibodies may be the key to laying a foundation for COVID-19 treatment, according to a Chinese research team led by Peking University.    The worldwide race against the clock to develop an effective coronavirus vaccine has been underway since early 2020. University research teams, public and private…

Coronavirus At the 28 May 2020 IFPMA media briefing on COVID-19 vaccines, Pfizer chairman and CEO Dr Albert Bourla outlined why the US firm had decided to take a different tack to that of its rivals in developing a vaccine using the innovative but as yet unproven Messenger RNA (mRNA) technology…

Europe The EFPIA’s Nathalie Moll gives an insight into the work underway across the European pharmaceutical industry to battle COVID-19 in terms of supporting organisations on the ground, ensuring the supply of medicines, and working on the research and development of treatments, vaccines, and diagnostics. Moll also outlines the vital importance…

Coronavirus During the 28 May 2020 IFPMA media briefing on COVID-19 vaccines, four of the pharmaceutical industry’s leading executives discussed where their firms are in the race to find a vaccine, the unprecedented levels of speed and collaboration being seen, and the challenges that lie ahead. Here we present five of…

Coronavirus In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the US would get priority access to a COVID-19 vaccine. He explained the firm’s collaboration with US research group BARDA and underscored that Sanofi is committed to bringing vaccines to all…